In November 2025, BMO Capital initiated coverage with a "Market Perform" rating and a $100 price target, and HealthEquity announced its third-quarter earnings date. In December 2025, Barrington Research maintained an "Outperform" rating with a $125 price target, and an executive VP & CTO sold 10,959 shares. In January 2026, the company issued an upbeat fiscal 2027 outlook, but shares fell by 10.19%. In February 2026, HealthEquity reported record Q4 and fiscal 2026 sales metrics, including adding over one million new HSA accounts, which led to a 3.7% gain in shares, and reaffirmed its guidance for fiscal 2026 and 2027. In March 2026, HealthEquity reported record revenue, earnings, and new HSAs from sales for the fourth quarter and year ended January 31, 2026, and raised its fiscal 2027 outlook, resulting in a minor 0.21% stock movement. Deutsche Bank raised its price target to $128, while Royal Bank of Canada cut its target to $100, and the company appointed Sanford Health CEO Bill Gassen to its Board of Directors. In April 2026, BMO Capital upgraded HealthEquity to "Outperform" and raised its price target to $105, citing renewed conviction in the HSA administrator's growth outlook, which contributed to a surge in shares. An executive VP & CTO notified an intention to sell 18,000 shares, and HealthEquity announced executive changes, with the CTO's employment terminated and a new EVP overseeing the technology organization. In May 2026, HealthEquity announced plans to release its first-quarter fiscal 2027 financial results on May 28, 2026, and confirmed participation in several investor conferences.
